| 2007 |
Dr. Tatjana Reinholz |
Life cycle management of a marketed medicinal product in view of GMP and regulatory requirements and impact of Product Quality Reviews *** |
|
|
| 2007 |
Dr. Silvia Sanner |
Registration Procedures in South Africa |
|
|
| 2007 |
Dr. Peter Satter |
Assessment of potential similarity between orphan drugs |
|
|
| 2007 |
Dr. Katja Schepper |
Clinical requirements for the development of biosimilar products *** |
|
|
| 2007 |
Dr. Ursula Schickel |
The impact of the revised EU-legislation concerning particular needs of blind and partially-sighted patients and user testing a challenge for pharmaceutical companies with focus on Germany *** |
|
|
| 2007 |
Dr. Dirk Schmidt |
Impact and Consequences of the PAT Initiatives by FDA and EMEA on New Chemical Entity Synthesis *** |
|
|
| 2007 |
Dr. Sabine Schmitz |
Pharmaceutical Excipients Regulatory and GMP Requirements *** |
|
|
| 2007 |
Karin Schöpf |
Global Pharmaceutical Markets and the Influence of the International Organizations WHO and ICH *** |
|
|
| 2007 |
Dr. Desi W. Soegiarto |
Changes of Pharmacovigilance Requirements within the Scope of Volume 9A and Related EU Guidelines |
|
|
| 2007 |
Dr. Susanne Sommer |
Package Leaflets: Testing and harmonisation in relation to the overall business process in regulatory procedures - An example of the impact of changing regulatory requirements *** |
|
|
| 2007 |
Seval Tangut |
New Regulatory Environment in Turkey |
|
|
| 2007 |
Dr. Dagmar Theis |
Legal Framework for Compassionate Use in the European Union - Comparison of the Implementation of Compassionate Use Programmes by Means of Selected European Member States |
|
|
| 2007 |
Sabine Wägele |
The Global Marketing Authorisation according to Article 6 of Directive 2001/83/EC, as amended *** |
|
|
| 2007 |
Dr. Nicole Wagner |
International Nonproprietary Names (INNs) - A Critical Issue For Biological Medicinal Products *** |
|
|
| 2007 |
Dr. Michael Walser |
Analytical Method Validation: Compilation of Relevant Legislation, Guidelines, and Literature |
|
|
| 2007 |
Johanna Walter, (geb. Bleicher) |
The new CMD(h) - a chance for reaching agreement in MRP and DCP? *** |
|
|
| 2007 |
Martin Watzl |
The New Paediatric Regulation in the EU - Development, Implications and Comparison with US Experiences in Paediatric Drug Development *** |
|
|
| 2007 |
Tanja Weber |
A Step Beyond Module 3 of Biodegradable Implants *** |
|
|
| 2007 |
Dr. Tong Zhang |
Audit Check List for Sterile Active Pharmaceutical Ingredients |
|
|
| 2007 |
Dr. Stefan Zwilling |
Monoclonal antibodies developed as anticancer drugs: EU clinical trial application with focus on IMPD requirements *** |
|
|